期刊文献+

程序性细胞死亡受体1基因多态性与慢性HCV感染及抗病毒疗效的关系 被引量:3

Association of programmed cell death-1 gene polymorphisms with chronic hepatitis C virus infection and antiviral effect
下载PDF
导出
摘要 目的探明程序性细胞死亡受体1(PD-1)基因单核苷酸多态性(SNP)与慢性HCV感染及IFN联合利巴韦林抗HCV疗效的关系。方法选择2010年10月-2012年10月在河北省7家医院住院的慢性丙型肝炎(CHC)患者228例,采用IFN联合利巴韦林个体化方案进行抗病毒治疗,健康体检者81例作为对照组。Taq Man探针法检测PD-1基因多态性,分析患者及对照组PD-1.1及PD-1.3位点等位基因及基因型分布差异,并分析PD-1.1及PD-1.3位点SNP与抗HCV疗效的关系。计数资料组间比较采用χ~2检验。结果 CHC患者组PD-1.1位点T等位基因、TT基因型携带率显著高于对照组(52.41%vs 43.21%,χ~2=4.059,P=0.044;28.51%vs 14.81%,χ~2=6.469,P=0.039);PD-1.1位点等位基因型分布在是否获得完全早期病毒学应答、是否获得持续病毒学应答的患者间差异均无统计学意义(P值均〉0.05)。PD-1.3位点在CHC患者及对照组均为CC型。结论 PD-1.1位点T等位基因可能与HCV慢性感染有关,TT基因型携带者HCV慢性感染风险可能较高。PD-1.1位点基因多态性与抗HCV治疗病毒学应答无明确关系。 Objective To investigate the association of single nucleotide polymorphisms( SNPs) of programmed cell death- 1( PD- 1)gene with chronic hepatitis C virus( HCV) infection and the effect of antiviral therapy with interferon combined with ribavirin. Methods A total of 228 patients with chronic hepatitis C( CHC) who were hospitalized in seven hospitals in Hebei Province,China from October 2010 to October 2012 were enrolled and treated with interferon combined with ribavirin as the individualized antiviral therapy. Eighty- one persons who underwent physical examination were enrolled as control group. The Taq Man probe method was used to detect PD- 1 gene polymorphisms. The distribution of alleles and genotypes at PD- 1. 1 and PD- 1. 3 were compared between the two groups,and the association between the SNPs of PD- 1. 1 and PD- 1. 3 and anti- HCV effect was analyzed. The chi- square test was used for the comparison of categorical data between groups. Results The CHC group showed significantly higher frequencies of T allele and TT genotype at PD- 1. 1 than the control group( 52. 41% vs 43. 21%,χ~2= 4. 059,P = 0. 044; 28. 51% vs 14. 81%,χ~2= 6. 469,P = 0. 039). The SNPs of PD- 1. 1 gene were not significantly associated with complete early virologic response or sustained virologic response( both P〉 0. 05). Both groups had CC genotype at PD- 1. 3. Conclusion PD- 1. 1 T allele might be associated with chronic HCV infection,and patients carrying TT genotype have a high risk of chronic HCV infection. PD- 1. 1 polymorphism is not associated with virologic response to anti- HCV therapy.
出处 《临床肝胆病杂志》 CAS 2016年第9期1721-1724,共4页 Journal of Clinical Hepatology
基金 河北省卫生厅科研基金项目(重点科技研究计划)(20130227) 河北省卫生厅科研基金项目(20140089) 河北省科学技术研究与发展计划项目(10276102D)
关键词 肝炎 丙型 慢性 多态性 单核苷酸 程序性细胞死亡受体1 hepatitis chronic polymorphisms single nucleotide programmed cell death-1
  • 相关文献

参考文献15

  • 1LAVANCHY D. The global burden of hepatitis C[J]. Liver Int,2009,29( Suppl 1) : 74 - 81.
  • 2FAWZY MM,WAHID A,NAZMY MH,et al. Association of inter-leukin - 27 rs 153109 single nucleotide polymorphism with sponta-neous resolution of hepatitis C virus - genotype 4a infection in egyp-tian patients[J]. Asian Pac J Cancer Prev,2016,17( 4) : 2093 -2097.
  • 3YANG Y,LIU H. Association between interleukin - 18 gene pro-moter ( - 607C / A and - 137G / C ) polymorphisms and chronichepatitis C virus infections: a meta - analysis[J]. Meta Gene,2015,5: 21 - 31.
  • 4NADIA K,HICHAM E,REDA TM,et al. The complete title: Theeffect of interleukin - 28B rs12979860 polymorphism on the thera-peutic response of Moroccan patients with chronic hepatitis C[J].Gene,2015,568( 1) : 31 - 34.
  • 5KAWAOKA T,HAYES CN,OHISHI W,et al. Predictive value ofthe IL28B polymorphism on the effect of interferon therapy in chron-ic hepatitis C patients with genotypes 2a and 2b[J]. J Hepatol,2011,54( 3) : 408 - 414.
  • 6LIU C,JIANG J,GAO L,et al. A promoter region polymorphismin PDCD - 1 gene is associated with risk of rheumatoid arthritis inthe Han Chinese population of Southeastern China[J]. Int J Ge-nomics,2014,2014: 247637.
  • 7MAHMOUDI M,REZAIEMANESH A,SALMANINEJAD A,et al.PDCD1 single nucleotide genes polymorphisms confer susceptibilityto juvenile - onset systemic lupus erythematosus[J]. Autoimmuni-ty,2015,48( 7) : 488 - 493.
  • 8ZHANG G,LI N,ZHANG P,et al. PD - 1 mRNA expression isassociated with clinical and viral profile and PD1 3 ' - untranslatedregionpolymorphism in patients with chronic HBV infection[J]. Im-munol Lett,2014,162( 1 Pt A) : 212 - 216.
  • 9SU SS,HE H,KONG LB,et al. Regulatory phenotype,PD - 1 andTLR3 expression in T cells and monocytes from HCV patients undergo-ing antiviral therapy: a randomized clinical trial[J]. PLo S One,2014,9( 4) : e93620.
  • 10URBANI S,AMADEI B,TILA D,et al. Restoration of HCV - spe-cific T cell functions by PD - 1 / PD - L1 blockade in HCV infec-tion: effect of viremia levels and antiviral treatment[J]. J Hepatol,2008,48( 4) : 548 - 558.

二级参考文献28

  • 1许镇,张晓红,赵志新,林潮双,蔡庆贤,谢冬英,高志良.高病毒载量慢性丙型肝炎快速病毒学应答的预测因素分析[J].中华临床医师杂志(电子版),2011,5(18):5327-5330. 被引量:4
  • 2Mohammad Irshad,Dhananjay Singh Mankotia,Khushboo Irshad.An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World Journal of Gastroenterology,2013,19(44):7896-7909. 被引量:56
  • 3丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 4van der MEER AJ, VELDT BJ, FELD JJ, et al. Associationbetween sustained virological response and all - cause mor-tality among patients with chronic hepatitis C and advancedhepatic fibrosis sustained virological response and all - causemortality[J]. JAMA, 2012,308(24) : 2584 -2593.
  • 5YU JW, WANG GQ, SUN LJ, et al. Predictive value of rapidvirological response and early virological response on sus-tained virological response in HCV patients treated with pegy-lated interferon alpha -2a and ribavirin[J]. J GastroenterolHepatol, 2007,22(6) : 832 -836.
  • 6HADZIYANNIS SJ, SETTE H JR, MORGAN TR, et al. Peginter-feron - alpha 2a and ribavirin combination therapy in chronichepatitis C: a randomized study of treatment duration and ribavi-rin dose[J]. Ann Intern Med, 2004, 140(5) : 346 -355.
  • 7FERENCI P, FRIED MW, SHIFFMAN ML, et al. Predicting sus-tained virological responses in chronic hepatitis C patients trea-ted with peginterferon alfa -2a (40 KD)/ribavirin[J]. J Hepa-tol, 2005, 43(3): 425 -433.
  • 8MANNS MP, MCHUTCHISON JG, GORDON SC, et al. Peginter-feron alfa -2b plus ribavirin compared with interferon alfa -2b plusribavirin for initial treatment of chronic hepatitis C:a randomized tri-al[J]. Lancet, 2001, 358(9286) : 958 -965.
  • 9CAMMA C, PETTA S, ENEAM,et al. Cost - effectivenessof boceprevir or telaprevir for untreated patients with geno-type 1 chronic hepatitis C[J]. Hepatology, 2012,56(3):850 -860.
  • 10GILL U,AZIZ H, GILL ML. Rapid virological response tailorsthe duration of treatment in hepatitis C virus genotype 3 pa-tients treated with pegylated interferon alfa —2a and ribavirinin Pakistan[ J]. Int J Infect Dis, 2013,17(11): e1017 -e1021.

共引文献225

同被引文献24

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部